Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Palatin Technologies

Status and phase: Completed; Phase 2

Conditions: Sexual Arousal Disorder

Treatments: Drug: Bremelanotide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00425256

PT-141-2005-53

Details and patient eligibility

About

This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.

Sex: Female

Ages: 21 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Post menopausal and in general good health
• In a stable relationship with a male partner for at least 6 months
• Willing to attempt sexual activity once a week with your partner